From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

blonca9
Nov 21, 2024
1 min read

CEO Jaewoo Kang, a computer scientist, describes AIGEN's computational heavy platform. Plus, he discusses three of the most advanced programs: a pan-KRAS inhibitor, USP1, and developing linkers and payloads to help Hanmi with ADCs.

Recent Posts

See All

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC

Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types

From Seoul: AIGEN Sciences is using generative AI for drug discovery and development - in addition to already having 16 programs, the company earlier this year struck an ADC deal with Hanmi

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight